BridgeBio Oncology Therapeutics, Inc.
BBOTCIK 0001869105 · last filing Jul 6, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
4,528,186 bought / 4,530,748 sold
net −2,562 sh · −$20.0K
- buys
- 3
- sells
- 5
- insiders active
- 5
Filing tape
Filed Mon, Jul 6, 2026
- ±0
Chen Bihua — Director · 10% owner
- Disposed of4,528,186Common Stock→ 0 held
- Acquired2,692,459Common Stock→ 4,879,995 held
- Acquired1,704,862Common Stock→ 5,010,332 held
- Acquired130,865Common Stock→ 6,083,221 held
- −125 sh · $975
Cobo Marc — Principal Accounting Officer
- Withheld for tax125Common Stock@ $7.80→ 5,306 held
- −343 sh · $2.7K
Elmelech Idan — COO & Principal Financial Ofcr
- Withheld for tax343Common Stock@ $7.80→ 14,495 held
- −1,047 sh · $8.2K
Ben Yong — Chief Med & Dev Officer
- Withheld for tax1,047Common Stock@ $7.80→ 44,576 held
- −1,047 sh · $8.2K
Beltran Pedro — President and CEO · Director
- Withheld for tax1,047Common Stock@ $7.80→ 44,576 held
Insiders on this tape
- Chen BihuaDirector · 10% owner
- Cobo MarcPrincipal Accounting Officer
- Elmelech IdanCOO & Principal Financial Ofcr
- Ben YongChief Med & Dev Officer
- Beltran PedroPresident and CEO · Director
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.